Anti-cancer drugs clinical trial data

The US clinical trial data for some recently approved anti-cancer drugs is still secret some years later.

The US government should stop negotiating with those exploitative companies and legislate that the US government can and will publish those studies as soon as the drug is approved. Or perhaps as soon as the application for approval is filed.

The biggest companies tend to want to increase their trade secrecy to gain more advantage over competitors. But what is good for the public is to give the biggest companies less advantage over competitors. Therefore, whenever there is a public-interest reason to demand that companies come clean about their operations, we should make that a legal requirement.